HEMATOLOGY

Jorge J. Castillo, MD, will explore the challenges of managing WM. He will present on September 30, 2022, at 11:04 AM.

Andrew A. Lane, MD, PhD, discusses the study design of a phase 1/2 trial of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasms.

Lionel Adès, MD, PhD, discussed emerging targeted therapies for myelodysplastic syndromes during a presentation at the 10th Annual Meeting of the Society of Hematologic Oncology.

Combinations of the BCL2 inhibitor venetoclax with hypomethylating agents are undergoing investigation to determine benefit in high-risk myelodysplastic syndrome.

In the myeloma space, minimal residual disease negativity is prognostic of progression-free survival in relapsed or refractory patients. In leukemia, the biomarker combined with other prognostication techniques provides complex information that is clinically relevant.

An overview of the single-cell level in early stage disease and describe new molecular classifications of myelodysplastic syndrome.

Opening the discussion on the management of BPDCN, an expert panel consisting of two hematologist-oncologists and a pathologist, considers the causes, incidence and diagnostic approach to this rare disease.

The FDA has approved eflapegrastim-xnst injection for adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs linked with clinically significant incidence of febrile neutropenia.

Ronald S. Go, MD, discusses what community oncologists should know regarding the guidelines on managing patients with histiocytic neoplasms.

Pegfilgrastim-fpgk has been approved by the FDA for patients with febrile neutropenia following data which revealed it to have a high degree of similarity with its reference product.

Data from the phase 2 CADENZA trial revealed front-line pivekimab sunirine to demonstrate clinical activity in patients with blastic plasmacytoid dendritic cell neoplasm.

Nicolas Gazeau, MS, discusses next steps and unmet needs following a positive retrospective study of anakinra for the management of neurotoxicity and cytokine release syndrome in patients who received chimeric antigen receptor T-cell therapy.

Jeffrey Miller, MD, discusses what is next to come following an analysis of GTB-3550.

An investigational new drug application has been accepted by the FDA allowing for the start of a phase 1 trial to evaluate the tolerability of CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies

Approval has been granted by the FDA to pemigatinib for the treatment of patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement based on the phase 2 FIGHT-203 trial.

During a Targeted Oncology case-based roundtable event, Daniel R. Couriel, MD, MS, MBA, discussed how to predict risk of acute graft-vs-host-disease and manage its effects on patients with hematologic malignancies.

Findings from.the phase 1/2 IMAGINE have led the FDA to approve ibrutinib for select pediatric and young adult patients with chronic graft-versus-host disease.

Approval has been granted by the FDA to betibeglogene autotemcel for the treatment of patients with beta-thalassemia based on multiple phase 3 studies.

Pivotal phase 3 result have led the FDA to accept a biologics license applications for omidubicel as treatment of patients with blood cancers requiring allogenic hematopoietic stem cell transplant. The applications has been accepted for priority review.

During a Targeted Oncology case-based roundtable event, Hana F. Safah, MD, discussed risk factors for acute graft-versus-host disease and data supporting treatment for steroid-refractory disease.

Hagop M. Kantarjian, MD, discusses the impact of prominent treatments in acute lymphoblastic leukemia.

Following positive phase 1 study results for eltanexor monotherapy in patients with relapsed or refractory intermediate, high-, or very high-risk myelodysplastic syndrome, the FDA has granted the drug fast track status.

According to an analysis of 161 trials, patients and physicians should be encouraged to use phase 1 trials for meaningful therapy.

The FDA has granted fast track designation to abelacimab for the treatment of thrombosis associated with cancer. The agent is being assessed in 2 phase 3 clinical trials.

Gunther Koehne, MD, PhD, discusses his hopes for future advances for patients with hematologic malignancies.